Fig. 2
Wnt1 impairs adaptive immune surveillance in syngeneic models. a Expression of Wnt1 and active b-catenin (western blot) in LLC cells transduced with Wnt1 (Wnt1) or Empty (Empty) viral vectors (Up). In vitro proliferation (MTT assay) (Bottom). b, c Tumor burden (total absolute number of LLC cells) after intrathoracic (i.t.) implantation or intravenous (i.v.) administration. d Cellular profiles of lung tumors. Pies depict mean percentages among CD45+ cells. e Numbers of intratumoral cDCs, CD8 T, CD4 T, and B cells per cancer cell. f Tumor growth after subcutaneous implantation of ovalbumin (OVA)-LLC cells in immunocompetent vs. immunodeficient RAG mice. g Numbers of OVA-specific (dextramer+) T cytotoxic cells per cancer cell and T cell CD44 expression. h Expression of Wnt1 and active b-catenin (western blot) in LLC cells transduced with shWnt1 or Scramble viral vectors (left). In vitro proliferation (MTT assay) (right). i Tumor burden (total absolute number of OVA-LLC cells) after intrathoracic (i.t.) implantation in untreated vs. aCD8-treated mice (left). Numbers of dextramer+ T cytotoxic cells per cancer cell and T cell PD1 expression (Right). a–i Error bars represent mean with SEM. b–g, i Cell numbers and profiles were assessed by FACS. Data are representative or cumulative of at least two independent experiments with 5–9 mice per group. *p < 0.05; **p < 0.01, Mann–Whitney. Source data are provided as a Source Data file
